MX2020010722A - Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. - Google Patents

Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.

Info

Publication number
MX2020010722A
MX2020010722A MX2020010722A MX2020010722A MX2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A MX 2020010722 A MX2020010722 A MX 2020010722A
Authority
MX
Mexico
Prior art keywords
antibodies
graft rejection
prevention
therapies
kits
Prior art date
Application number
MX2020010722A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Espie
James Rush
Boerje Haraldsson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020010722A publication Critical patent/MX2020010722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020010722A 2018-04-13 2019-04-11 Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos. MX2020010722A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862657172P 2018-04-13 2018-04-13
EP18208332 2018-11-26
PCT/IB2019/052976 WO2019198019A1 (en) 2018-04-13 2019-04-11 Anti-cd40 antibodies for use in prevention of graft rejection

Publications (1)

Publication Number Publication Date
MX2020010722A true MX2020010722A (es) 2020-11-06

Family

ID=66542473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010722A MX2020010722A (es) 2018-04-13 2019-04-11 Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.

Country Status (13)

Country Link
US (2) US11780927B2 (https=)
EP (1) EP3774913A1 (https=)
JP (2) JP6861301B2 (https=)
KR (1) KR20200143718A (https=)
CN (1) CN111971307A (https=)
AU (1) AU2019252858A1 (https=)
BR (1) BR112020020277A2 (https=)
CA (1) CA3094600A1 (https=)
CL (1) CL2020002622A1 (https=)
IL (1) IL277828A (https=)
MX (1) MX2020010722A (https=)
TW (1) TW201943731A (https=)
WO (1) WO2019198019A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225736A1 (en) * 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
WO2022090194A1 (en) * 2020-10-26 2022-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for assessing the area under the curve of an immunosuppressant and associated method and systems
EP4402174A1 (en) * 2021-09-17 2024-07-24 Novartis AG Methods for prevention of graft rejection in xenotransplantation
WO2025117849A1 (en) * 2023-11-28 2025-06-05 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025235683A1 (en) * 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Methods and compositions for prevention of transplant rejection
WO2025235670A1 (en) 2024-05-07 2025-11-13 Eledon Pharmaceuticals, Inc. Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
BRPI0417266B8 (pt) 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
CN101014386A (zh) * 2004-04-27 2007-08-08 诺华疫苗和诊断公司 拮抗性抗－cd40单克隆抗体及其使用方法
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
BR112012024713B1 (pt) 2010-03-31 2021-02-17 Boehringer Ingelheim International Gmbh anticorpo humanizado, seus usos e composição farmacêutica que o compreende
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US11780977B2 (en) * 2020-08-10 2023-10-10 Dover Chemical Corporation Polymer compositions having an improved printable surface and related methods

Also Published As

Publication number Publication date
CL2020002622A1 (es) 2021-04-16
KR20200143718A (ko) 2020-12-24
JP2021113190A (ja) 2021-08-05
WO2019198019A1 (en) 2019-10-17
CA3094600A1 (en) 2019-10-17
JP2020519634A (ja) 2020-07-02
EP3774913A1 (en) 2021-02-17
US11780927B2 (en) 2023-10-10
US20240287198A1 (en) 2024-08-29
AU2019252858A1 (en) 2020-10-08
IL277828A (en) 2020-11-30
CN111971307A (zh) 2020-11-20
TW201943731A (zh) 2019-11-16
BR112020020277A2 (pt) 2021-01-19
US20210079107A1 (en) 2021-03-18
JP6861301B2 (ja) 2021-04-21

Similar Documents

Publication Publication Date Title
MX2020010722A (es) Anticuerpos anti-cd40 para uso en la prevencion del rechazo de injertos.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
MY205760A (en) Humanized antibodies against c-kit
PH12020552229A1 (en) Il-11ra antibodies
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
JOP20190283B1 (ar) طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها
MY208231A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
MX2021000027A (es) Anticuerpos anti-factor de la coagulacion xi.
EA201790439A1 (ru) Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
PH12020552235A1 (en) Anti-cd40 antibodies for use in treating autoimmune disease
MX2021013631A (es) Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis.
ZA202309516B (en) Anti-ccr8 antibodies
PH12018502586A1 (en) Anti-coagulation factor xi antibodies
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
WO2018148486A8 (en) Anti-factor d antibodies and uses thereof
EP4588484A3 (en) Methods of treating multiple myeloma
EA201691634A1 (ru) Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l